MolDX: Minimal Residual Disease Testing for Cancer Final LCD - Effective January 02, 2022

This Local Coverage Determination (LCD) has completed the Open Public Meeting and is now finalized under contractor numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV). Responses to comments received may be found as a link at the bottom of the final LCD.

Medicare Coverage Database (MCD) Number/Contractor Determination Number: L38814

LCD Title: MolDX: Minimal Residual Disease Testing for Cancer

Effective Date: January 02, 20222

Summary of LCD: Limited coverage for minimally invasive molecular deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) tests that detect minimal residual disease (MRD) in patients with a personal history of cancer.

Visit the Proposed LCDs webpage to access this LCD.

 

            Last Updated Tue, 23 Nov 2021 15:31:43 +0000